M&A

CVS To Close Signify Health Deal, Launching A National In-Home Care Business
CVS To Close Signify Health Deal, Launching A National In-Home Care Business
Forbes
CVS Health
M&A
Signify Health
home healthcare
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Flag link:
Baxter attracts Thermo Fisher, Celltrion as potential buyers for biopharma contracting business
Baxter attracts Thermo Fisher, Celltrion as potential buyers for biopharma contracting business
Fierce Pharma
Baxter
Thermofisher
Celltrion
M&A
CMOs
Flag link:
Illumina, facing Icahn challenge, ‘moving quickly’ on resolution for Grail
Illumina, facing Icahn challenge, ‘moving quickly’ on resolution for Grail
BioPharma Dive
Illumina
Grail
M&A
Medtech
diagnostics
Carl Icahn
Flag link:
Pear Therapeutics Looks For A Buyer As It Struggles To Get Paid For Prescription Apps
Pear Therapeutics Looks For A Buyer As It Struggles To Get Paid For Prescription Apps
Forbes
Pear Therapeutics
digital therapeutics
FDA
Medtech
insomnia
M&A
Flag link:
Concentra's Buy Offer May Jeopardize Jounce's Merger with Redx
Concentra's Buy Offer May Jeopardize Jounce's Merger with Redx
BioSpace
Jounce Therapeutics
Redx
Concerta
M&A
Flag link:
In Pfizer-Seagen review, FTC has chance to set new pharma precedent
In Pfizer-Seagen review, FTC has chance to set new pharma precedent
BioPharma Dive
FTC
Pfizer
Seagen
M&A
antitrust
anticompetitive practices
Flag link:
Pfizer CEO points to IRA as a factor that made Seagen an attractive target
Pfizer CEO points to IRA as a factor that made Seagen an attractive target
Endpoints
Pfizer
Seagen
M&A
Inflation Reduction Act
Flag link:
Illumina Responds to Icahn Partners' Nomination of Directors
Illumina Responds to Icahn Partners' Nomination of Directors
BioSpace
Illumina
Carl Icahn
M&A
Grail
Flag link:
Pfizer to buy Seagen in $43B cancer drug deal
Pfizer to buy Seagen in $43B cancer drug deal
BioPharma Dive
Pfizer
Seagen
M&A
lymphoma
Adcetris
Flag link:
Carl Icahn takes proxy fight to Illumina: report
Carl Icahn takes proxy fight to Illumina: report
Endpoints
Illumina
Grail
M&A
Carl Icahn
Flag link:
Sanofi throws down $2.9B to acquire diabetes partner Provention Bio
Sanofi throws down $2.9B to acquire diabetes partner Provention Bio
Fierce Pharma
Sanofi
Provention Bio
M&A
diabetes
Flag link:
Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business
Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business
Motley Fool
Pfizer
Seagen
M&A
Flag link:
Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline
Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline
Fierce Biotech
Adaptimmune Therapeutics
TCR2 Therapeutics
M&A
Flag link:
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Fierce Pharma
Bristol Myers Squibb
Breyanzi
Celgene
legal
M&A
CVRs
Flag link:
Latest biotech-on-biotech merger sees aimless Adamis snapped up by DMK
Latest biotech-on-biotech merger sees aimless Adamis snapped up by DMK
Fierce Biotech
Adamis Pharmaceuticals
DMK Pharmaceuticals
M&A
COVID-19
Flag link:
Medtech’s M&A Scene Stays Hot with Olympus Deal
Medtech’s M&A Scene Stays Hot with Olympus Deal
Medical Devices and Diagnostics Industry
devices
Medtech
M&A
Olympus
Taewoong Medical
Flag link:
Seagen has a New Suitor as Pfizer Talks Begin
Seagen has a New Suitor as Pfizer Talks Begin
BioSpace
Seagen
Pfizer
M&A
Flag link:
Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx
Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx
BioSpace
Jounce Therapeutics
Redx
M&A
layoffs
Flag link:

Pages